Numerous studies have suggested that melatonin plays an important role in regulating Bmal1 and exhibits beneficial physiological influences in the intervention of aging‐associated diseases such as AD (Li, Zhang, et al., 2020), PD (Delgado‐Lara et al., 2020), T2DM (Abdulwahab et al., 2021), AS (Xie, Tang, et al., 2020), and OA (Hosseinzadeh et al., 2016). This evidence concerns the gene BMAL1 and Parkinson disease.